Nature Communications (Jul 2025)

Histone serotonylation promotes pancreatic cancer development via lipid metabolism remodeling

  • Sang Lin,
  • Sheng Tan,
  • Yonglin Peng,
  • Aziguli Tulamaiti,
  • Wenfei Du,
  • Keshuo Ding,
  • Changyu Chen,
  • Jun Wu,
  • Hua Li,
  • Wei Xu,
  • Jielin Sun,
  • Xue-Li Zhang,
  • Zhi-gang Zhang,
  • Xiaodong Zhao

DOI
https://doi.org/10.1038/s41467-025-61197-z
Journal volume & issue
Vol. 16, no. 1
pp. 1 – 14

Abstract

Read online

Abstract Neurotransmitter serotonin (5-hydroxytryptamine [5-HT]) has emerged to play parallel roles in both neurobiology and oncology. Apart from receptor-mediated signaling transduction pattern, serotonin can be covalently integrated into histone (the post-translational modification known as histone serotonylation) and serve as an epigenetic mark associated with permissive gene expression. However, how histone serotonylation influences tumorigenesis is yet to be understood. In this study, we observe the higher levels of histone serotonylation (H3K4me3Q5ser) and transglutaminases 2 (TGM2, the enzyme catalyzing serotonylation) in both pancreatic ductal adenocarcinoma (PDAC) tissues and cell lines in comparison with their normal counterparts, and inhibition of histone serotonylation suppresses PDAC development. Mechanistically, we demonstrate that TGM2-mediated histone serotonylation at promoter of the gene encoding stearoyl-CoA desaturase (SCD) up-regulates its expression and drives PDAC development by lipid metabolism remodeling. Collectively, this study reveals histone serotonylation as an important driver of PDAC tumorigenesis.